ClinicalTrials.gg
CompletedNCT04661163Updated Nov 25, 2024

CHALLENGE. A Randomised Clinical Trial Examining Virtual Reality Therapy

An interventional study of Psychotherapy in Auditory Hallucinations, sponsored by Mental Health Services in the Capital Region, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Mental Health Services in the Capital Region, Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is a randomised, assessor-blinded parallel-groups superiority clinical trial, allocating a total of 266 patients to either the experimental intervention or standard intervention. The participants will be randomised to either 12-weeks of virtual reality therapy or supportive counselling. All participants will be assessed at 12- and 24 weeks post baseline. A stratified block-randomisation with concealed randomisation sequence will be conducted. Independent assessors blinded to the treatment will evaluate outcome. Analysis of outcome will be carried out with the intention to treat principles.

Read the detailed description

Auditory hallucinations are among the most frequent symptoms in psychotic disorders. While a large group of patients with first episode psychosis achieve remission of psychotic symptoms during first year after initial contact with mental health services, almost one third continue having psychotic symptoms in spite of treatment with antipsychotic medication. Since auditory hallucinations are a major cause of distress and suffering for these patients, there is an essential need to test the effectives of targeted psychotherapeutic interventions in alleviating auditory hallucinations Two previous trials have provided preliminary evidence of the effectiveness of virtual reality therapy on auditory hallucinations, but no trial to date has examined the effect of virtual reality assisted therapy in an adequately powered RCT. In this large-scale randomized, clinical trial, patients in the experimental intervention will be receiving 7 sessions of virtual reality assisted avatar therapy while patients in the control group will receive 7 sessions of supportive contact with mental health care professionals at their regular outpatient clinic.

If the virtual reality therapy is found to be beneficial in reducing the severity of refractory auditory hallucinations, it will be a breakthrough in the current treatment of psychotic disorders. A large group of patients with schizophrenia and related disorders in Denmark and worldwide will be the target group of the therapy. If proven effective, the treatment will be especially relevant for patients with treatment resistant schizophrenia, but the treatment can also be used as an add on to antipsychotic medication for patients with a better prognosis, such as patients with first episode psychosis. If the virtual reality therapy is proven effective, it can be implemented in mental health services in Denmark and internationally. A successful implementation could reduce the costs associated with treatment of schizophrenia.

02

Conditions studied

  • Auditory Hallucinations

Keywords

  • Avatar
  • Schizophrenia
  • Auditory Hallucinations
  • Psychotherapy
  • Virtual Reality
  • Psychosis
  • Virtual Reality Therapy
03

In context

Hallucinations

136 studies on the registry are indexed under Hallucinations; 35 are open to participants now.

This study's enrollment of 270 is above the median of 48 across 118 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

Mental Health Services in the Capital Region, Denmark is the lead sponsor of 49 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 - years
  2. Ability to give
  3. A schizophrenia spectrum disorder (ICD-10 code: F20 -F29)
  4. Auditory hallucinations for at least three months, corresponding to a SAPS score on auditory hallucinations of ≥3.
  5. No changes in antipsychotic medication within the past four weeks and

    1. Not responding to current antipsychotic compound or
    2. Not responding to at least two antipsychotic compounds. Table2

Exclusion criteria

Exclusion Criteria:

  1. Rejecting
  2. Unable to identify a single dominant voice to work on
  3. A diagnosis of organic brain disease
  4. Substance to a level that hinders engagement in therapy.
  5. Auditory hallucinations in a language not spoken by the therapists
  6. A command of spoken Danish or English inadequate for engaging in therapy
  7. Inability to tolerate the assessment process
  8. Strongly impaired vision
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    Virtual reality avatar therapy

    Patients will be offered seven individual sessions of virtual reality therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 50 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.

    Other: Psychotherapy

  • No intervention
    Supportive counselling (comparison group)

    The control group is offered seven session with health professionals providing supportive counselling. This can (but does not necessarily) involve psychotherapy targeting auditory hallucinations.

Interventions

  • OtherPsychotherapy

    Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations

    Also known as: Virtual Reality Avatar Therapy

06

What researchers measure

Primary outcomes

  1. Level of auditory hallucinations

    Level of auditory hallucinations measured with The Psychotic Symptoms Rating Scales (PSYRATS-AH) total score at cessation of treatment at 12-weeks (score on PSYRATS-AH: 0-44. A score of 0 is the minimum score and 44 is the maximum score i.e. a score of 44 is the worst possible outcome.

    Time frame: 12 weeks from inclusion

Secondary outcomes

  1. Frequency of auditory hallucinations

    PSYRATS-AH-Frequency.

    Time frame: 12 weeks from inclusion

  2. Distress caused by auditory hallucinations

    PSYRATS-AH-Distress

    Time frame: 12 weeks from inclusion

  3. Voice acceptance

    Questionnaire: the Voices Acceptance and Action Scale (VAAS-Action)

    Time frame: 12 weeks from inclusion

  4. Assertive Responding to Voices

    Questionnaire: Assertive Responding to Voices (Approve - Voices), The assertive subscale (5 items with scores from 0-10, minimum score on this subscale is 0, maximum score is 50 with higher scores being a better outcome)

    Time frame: 12 weeks from inclusion

  5. Personal and social performance

    The personal and social performance scale (PSP); (Scores from 1-100, with a score of 100 being the best possible outcome).

    Time frame: 12 weeks from inclusion

  6. Perceived voice power

    Questionnaire: Voice Power Differential Scale, total score (range 7-35 with 7 being the minimum score and 35 the maximum score. Higher scores indicates greater power differential in favour of the voice - i.e. a worse outcome)

    Time frame: 12 weeks from inclusion

07

Study locations

1 site
  • Copenhagen Research Center for Mental Health - CORE
    Copenhagen, Hellerup 2900, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04661163
Lead sponsor
Mental Health Services in the Capital Region, Denmark
Collaborators
Mental Health Services in the Region of Southern Denmark, Mental Health Services in the North Denmark Region
Responsible party
Sponsor
First posted
Dec 10, 2020
Start date
Nov 16, 2020
Primary completion
Feb 27, 2024
Completion
Apr 2, 2024
Last update
Nov 25, 2024

Study contacts

Merete Nordentoft, professor
principal investigator · Mental Health Services Capitol of Denmark; Copenhagen Research Center for Mental Health - CORE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion